1. New Zealand Stocks

  2. •

    Health technology

  3. •

    Medical specialties
Fisher & Paykel Healthcare Corporation Limited

Fisher & Paykel Healthcare Corporation Limited

25.00
EUR
-0.40
(-1.57%)
0.39EPS
45.61P/E
10.63BMarket Cap
Nov 26Next Earn
Fisher & Paykel Healthcare Corporation Limited
GETTEX:FPLB
(Gettex)

Recent

price

25.00

P/E

ratio

45.61

div

yld

0.85%

ROIC.AI

2011
2012
2013
2014
2015
2016
2017
2018
2019
2020
2021
2022
2023
2024
2025
2026
NZD
1.23
1.12
1.17
1.11
1.18
1.62
1.67
1.79
1.95
2.22
3.38
2.85
2.75
3.02
2.19
3.93
Revenue per Share
0.14
0.15
0.18
0.19
0.21
0.28
0.33
0.35
0.38
0.5
0.91
0.65
0.43
0.23
0.64
0.8
Basic EPS, GAAP
0.02
0.02
0.02
0.13
0.17
0.13
0.22
- -
- -
- -
- -
- -
- -
- -
- -
- -
Free Cash Flow per Basic Share
0.18
0.17
0.16
0.14
0.09
0.13
0.17
0.19
0.21
0.25
0.31
0.39
0.34
0.25
0.33
0.43
Dividend per Share
0.82
0.83
0.86
0.79
0.86
1.07
1.27
1.41
1.66
1.69
2.64
2.91
3.03
3.01
3.24
3.6
Book Value per Share
0.8
0.81
0.84
0.77
0.82
1
1.19
1.32
1.55
1.57
2.5
2.76
2.88
2.86
3.1
3.48
Tangible Book Value per Share
517
526
538
547
556
561
566
570
573
574
576
577
578
582
586
587
Basic Weighted Avg Shares
635
589
631
607
656
907
948
1,023
1,118
1,273
1,948
1,642
1,589
1,758
1,280
2,308
Sales/Revenue/Turnover
7.71
3.83
6.89
9.68
16.32
21.24
19.68
21.14
23.09
25.76
31.02
22.55
15.15
14.47
-28.98
20.7
Operating Margin (%)
30
28
33
32
32
39
43
47
43
61
85
96
99
114
140
159
Depreciation Expense
71
81
96
104
115
159
184
202
218
287
524
377
250
133
377
469
Net Income, GAAP
43.47
30.55
29.56
28.98
28.72
28.58
29.06
28.98
28.16
22.46
27.01
25.25
23.69
43.74
25.05
25.81
Effective Tax Rate (%)
11.22
13.74
15.19
17.07
17.57
17.52
19.45
19.72
19.51
22.56
26.91
22.95
15.76
7.54
29.46
20.3
Profit Margin (%)
139
56
154
113
129
151
222
261
283
184
493
584
484
320
435
654
Working Capital
111
44
146
68
52
52
44
56
72
44
92
87
125
93
67
113
LT Debt
425
439
463
434
480
600
721
807
952
974
1,521
1,680
1,753
1,759
1,890
2,115
Total Equity
5.2
2.72
4.99
6.99
13.64
21.97
17.71
17.83
18.68
22.98
30.06
15.36
9.87
7.39
-13.61
15.89
Return on Invested Capital (%)
14.42
14.81
16.49
18.55
22.53
27.46
25.67
24.3
22.89
26.98
38.4
22.23
13.87
7.43
19.32
22.12
Return on Capital (%)
17.72
18.72
21.25
23.11
25.24
29.42
27.91
26.39
24.8
29.83
42.03
23.55
14.58
7.55
20.67
23.39
Return on Common Equity (%)

Capital Structure

NZD

•

in mil. unless spec.
No data availableFinancial data will appear here once available

Working Capital

NZD

•

in mil. unless spec.
No data availableFinancial data will appear here once available

Growth Rates

NZD

•

in mil. unless spec.

(avg. rate of change)

10 years
5 years
1 year
Total Equity
14.3%
6.9%
11.9%
Free Cash Flow
- -
- -
- -
Net Income, GAAP
24.77%
19.99%
24.2%
Sales/Revenue/Turnover
13.34%
8.96%
80.3%
Total Cash Common Dividend
14.57%
9.77%
28.79%

Semi-annual Revenue

NZD

•

in mil. unless spec.

Year

H1
H2
FY
2024
- -
- -
1,758
2025
- -
1,280
1,280
2026
- -
- -
2,308

Semi-annual Earnings Per Share

NZD

•

in mil. unless spec.

Year

H1
H2
FY
2024
- -
- -
0.23
2025
- -
0.64
0.64
2026
- -
- -
0.8

Semi-annual Dividends Per Share

NZD

•

in mil. unless spec.

Year

H1
H2
FY
2024
- -
- -
0.25
2025
- -
0.33
0.33
2026
- -
- -
0.43
Similar Companies
Intuitive Surgical, Inc. (NASDAQ:ISRG)
Boston Scientific Corporation (NYSE:BSX)
Thermo Fisher Scientific Inc (NYSE:TMO)
Illumina, Inc. (NASDAQ:ILMN)
Abbott Laboratories (NYSE:ABT)
GRAIL, Inc. (NASDAQ:GRAL)
Business
Fisher & Paykel Healthcare Corporation Limited designs, manufactures and markets innovative products and systems for acute and chronic respiratory care, surgery and obstructive sleep apnea treatment; core offerings span hospital humidification systems and breathing circuits, nasal high flow therapies including Optiflow, noninvasive ventilation interfaces, invasive ventilation consumables, surgical smoke evacuation and insufflation devices, homecare CPAP masks and devices such as Simplus, Eson, Evora and Forma full face masks alongside nasal pillows and cannulas, and accessories like chambers and software for data management. The company, founded in 1969 and headquartered in Auckland, New Zealand, operates globally with sales in over 120 countries, generating the majority of revenue from exports and employing over 7,500 people across manufacturing facilities including a new site in Tijuana, Mexico, and a planned facility in Guangzhou, China. Recent developments include FY24 revenue growth to NZ$1.74 billion with underlying net profit after tax up 6% to NZ$264 million despite a NZ$20 million product recall provision for pre-2017 devices and a NZ$98 million property write-down, alongside NZ$198 million in R&D investment supporting new mask launches and hospital product expansions; FY25 guidance projects revenue of NZ$1.9-NZ$2 billion and net profit of NZ$320-NZ$370 million driven by clinical practice shifts, manufacturing efficiencies lifting gross margins to 61.1%, and strategic capacity builds in key markets.

Company News

Company News APIChatGPT

  • seekingalpha.com

    Fisher & Paykel Healthcare Corporation Limited (FSPKF) Shareholder/Analyst Call Transcript

  • seekingalpha.com

    Fisher & Paykel Healthcare Corporation Limited (FSPKF) Q4 2026 Earnings Call Transcript

  • defenseworld.net

    Fisher & Paykel Healthcare (OTCMKTS:FSPKF) Stock Price Down 17.3% – Time to Sell?

  • seekingalpha.com

    Fisher & Paykel Healthcare Corporation Limited (FSPKF) Q2 2026 Earnings Call Transcript

  • seekingalpha.com

    Fisher & Paykel Healthcare Corporation Limited (FSPKF) Q4 2025 Earnings Call Transcript

  • seekingalpha.com

    Fisher & Paykel Healthcare Corporation Limited (FSPKF) Q2 2025 Earnings Call Transcript

  • seekingalpha.com

    Fisher & Paykel Healthcare Corporation Limited (FSPKF) Q4 2024 Earnings Call Transcript

  • seekingalpha.com

    Fisher & Paykel Healthcare Corporation Limited (FSPKF) Q2 2024 Earnings Call Transcript